35 results
Thumbnail

D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community

Thumbnail

D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results

Thumbnail

D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals

Thumbnail

D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach

Thumbnail

D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children

Thumbnail

D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels

Thumbnail

D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results

Thumbnail

D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency

Thumbnail

D1.309 - Association of Antenatal Corticosteroids with Risk of Autoimmune Diseases in Children: a Nationwide Cohort Study

Thumbnail

D1.308 - Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)

Thumbnail

D1.310 - Phenotypes of patients with Hereditary Angioedema (HAE): a case series

Thumbnail

D1.311 - Treatment Dilemmas in CARMIL2 Deficiency

Thumbnail

D1.312 - Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series

Thumbnail

D1.313 - Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center

Thumbnail

D1.315 - Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)

Thumbnail

D1.316 - Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease

Thumbnail

D1.317 - A Retrospective Analysis of Dengue-Associated Hemophagocytic Lymphohistiocytosis in a Dengue-Endemic Country

Thumbnail

D1.318 - Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data

Thumbnail

D1.319 - The Silent Threat of Hereditary Angioedema in Children: Single Center Experience

Thumbnail

D1.322 - A Prescription for Lower Immunity: The Hidden Cost of Certain Psychiatric Medications